Silence Therapeutics PLC - Asset Resilience Ratio
Silence Therapeutics PLC (SLN) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Silence Therapeutics PLC short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Silence Therapeutics PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Silence Therapeutics PLC assets under control.
Liquid Assets Composition Over Time
This chart breaks down Silence Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore SLN long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Silence Therapeutics PLC maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Silence Therapeutics PLC Industry Peers by Asset Resilience Ratio
Compare Silence Therapeutics PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Silence Therapeutics PLC (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Silence Therapeutics PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 56.17% | $73.84 Million | $131.44 Million | +43.34pp |
| 2024-12-31 | 12.83% | $20.77 Million | $161.85 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $94.53 Million | -- |
| 2022-12-31 | 15.19% | $16.33 Million | $107.50 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $96.19 Million | -- |
| 2020-12-31 | 11.63% | $10.00 Million | $85.97 Million | -31.78pp |
| 2019-12-31 | 43.41% | $20.00 Million | $46.08 Million | +30.44pp |
| 2018-12-31 | 12.97% | $5.04 Million | $38.88 Million | +12.39pp |
| 2017-12-31 | 0.58% | $319.00K | $55.01 Million | +0.57pp |
| 2016-12-31 | 0.01% | $3.00K | $55.79 Million | +0.00pp |
| 2015-12-31 | 0.00% | $2.00K | $61.55 Million | -16.79pp |
| 2014-12-31 | 16.79% | $5.00 Million | $29.77 Million | -0.27pp |
| 2013-12-31 | 17.06% | $5.00 Million | $29.30 Million | +17.05pp |
| 2012-12-31 | 0.01% | $2.00K | $17.07 Million | -0.10pp |
| 2011-12-31 | 0.11% | $37.51K | $33.44 Million | -- |
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated… Read more